Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

Dietrich A. Stephan net worth and biography

Dietrich Stephan Biography and Net Worth

CEO of NeuBase Therapeutics

Dr. Stephan is an industry veteran who is considered one of the fathers of the field of precision medicine, having trained with the leadership of the Human Genome Project at the NIH and then going on to lead discovery research at the Translational Genomics Research Institute and serve as professor and chairman of the Department of Human Genetics at the University of Pittsburgh. Stephan has identified the molecular basis of dozens of genetic diseases and published extensively in journals such as Science, the New England Journal of Medicine, Nature Genetics, PNAS and Cell. In parallel, Dr. Stephan has founded or co-founded 14 biotechnology companies and has advised an additional 12 companies. These companies are backed by the top-tier investors such as Sequoia Capital, KPCB, Thiel Capital, and Khosla Ventures as well as corporate partners such as Life Technologies, Pfizer, and Mayo Clinic. Dr. Stephan received his Ph.D. from the University of Pittsburgh and his BS from Carnegie Mellon University.

How old is Dietrich A. Stephan?: Dr. Stephan is currently 54 years old. There are 1 older executives and no younger executives at NeuBase Therapeutics. Learn More on Dietrich A. Stephan's age.
How do I contact Dietrich A. Stephan?: The corporate mailing address for Dr. Stephan and other NeuBase Therapeutics executives is 700 TECHNOLOGY DRIVE, PITTSBURGH PA, 15219. NeuBase Therapeutics can also be reached via phone at (164) 645-1790 and via email at [email protected]. Learn More on Dietrich A. Stephan's contact information.
Has Dietrich A. Stephan been buying or selling shares of NeuBase Therapeutics?: Dietrich A. Stephan has not been actively trading shares of NeuBase Therapeutics within the last three months. Most recently, on Monday, April 26th, Dietrich A. Stephan bought 600 shares of NeuBase Therapeutics stock. The stock was acquired at an average cost of $100.00 per share, with a total value of $60,000.00. Learn More on Dietrich A. Stephan's trading history.
Who are NeuBase Therapeutics' active insiders?: NeuBase Therapeutics' insider roster includes Eric Richman (Director), and Dietrich Stephan (CEO). Learn More on NeuBase Therapeutics' active insiders.
Are insiders buying or selling shares of NeuBase Therapeutics?: In the last twelve months, NeuBase Therapeutics insiders bought shares 1 times. They purchased a total of 61,076 shares worth more than $59,854.48. In the last twelve months, insiders at the sold shares 3 times. They sold a total of 207,336 shares worth more than $325,510.56. The most recent insider tranaction occured on September, 14th when Major Shareholder Corp Symetryx sold 129,108 shares worth more than $185,915.52. Insiders at NeuBase Therapeutics own 13.9% of the company. Learn More about insider trades at NeuBase Therapeutics.
Information on this page was last updated on 9/14/2023.

Dietrich A. Stephan Insider Trading History at NeuBase Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
4/26/2021	Buy	600	$100.00	$60,000.00
6/9/2020	Buy	63	$154.60	$9,739.80
5/21/2020	Buy	62	$159.80	$9,907.60
4/30/2020	Buy	500	$120.00	$60,000.00

Dietrich A. Stephan Buying and Selling Activity at NeuBase Therapeutics

NeuBase Therapeutics Company Overview

NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

Today's Range

Now: $0.40

$0.40

$0.42

50 Day Range

MA: $0.72

$0.40

$1.07

2 Week Range

Now: $0.40

$0.39

$5.40

Volume

68,205 shs

Average Volume

216,108 shs

Market Capitalization

$1.52 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

From Paradigm Press | Ad